Profile
Sector:
HealthcareCountry:
IsraelIPO:
28 January 2019Website:
http://www.intercure.coNext earnings report:
29 August 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 4 min agoDividend
Analysts recommendations
Institutional Ownership
INCR Latest News
InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates.
NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the six months ended June 30, 2024. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken.
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. This prestigious event will bring together senior management teams from leading cannabis companies including InterCu.
InterCure Ltd. (NASDAQ:INCR ) Q4 2022 Earnings Conference Call April 4, 2023 4:30 PM ET Company Participants Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Vivien Azer - Cowen and Company Matt Bottomley - Canaccord Genuity Pablo Zuanic - Zuanic & Associates Operator Thank you for standing by, and welcome to InterCure's Fourth Quarter 2022 Earnings Call.
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022.
What type of business is InterCure?
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
What sector is InterCure in?
InterCure is in the Healthcare sector
What industry is InterCure in?
InterCure is in the Drug Manufacturers - Specialty & Generic industry
What country is InterCure from?
InterCure is headquartered in Israel
When did InterCure go public?
InterCure initial public offering (IPO) was on 28 January 2019
What is InterCure website?
https://www.intercure.co
Is InterCure in the S&P 500?
No, InterCure is not included in the S&P 500 index
Is InterCure in the NASDAQ 100?
No, InterCure is not included in the NASDAQ 100 index
Is InterCure in the Dow Jones?
No, InterCure is not included in the Dow Jones index
When was InterCure the previous earnings report?
No data
When does InterCure earnings report?
The next expected earnings date for InterCure is 29 August 2025